Deborah Steensels

Prof. Deborah Steensels

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in JAMA
Verified
Journal Article
Open access
PDF file
DSDeborah Steensels
Deborah Steensels
NPNoella Pierlet
Noella Pierlet
JPJoris Penders
Joris Penders
DMDieter Mesotten
Dieter Mesotten
LHLine Heylen
Line Heylen
The SARS-CoV-2 messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have each shown more than 90% efficacy in preventing COVID-19 illness1,2 but, to our knowledge, humoral immune responses have not been compared directly.

14 July 2020 in JAMA
Verified
Journal Article
Open access
PDF file
DSDeborah Steensels
Deborah Steensels
EOEls Oris
Els Oris
LCLaura Coninx
Laura Coninx
DNDieter Nuyens
Dieter Nuyens
MDMarie-Luce Delforge
Marie-Luce Delforge
LHLine Heylen
Line Heylen
Belgium has a high burden of coronavirus disease 2019 (COVID-19), especially the region surrounding the Hospital East-Limburg, a tertiary care center.1 Infection prevention measures were instituted in the hospital beginning March 4, 2020, including testing and contact tracing of all symptomatic patients and staff, changes in hospital operations, and provision of personal protective equipment (PPE). The first case was detected March 13 (Figure 1). We investigated the prevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among hospital staff.

1 December 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
PVPraet Jens Van
Praet Jens Van
MRMarijke Reynders
Marijke Reynders
DBDirk De Bacquer
Dirk De Bacquer
LVLiesbeth Viaene
Liesbeth Viaene
MSMelanie Schoutteten
Melanie Schoutteten
AVAn S. De Vriese
An S. De Vriese
Significance Statement: Patients on hemodialysis characteristically have an impaired response to vaccination. This large multicenter cohort study found an incomplete and delayed humoral and a blunted cellular immune response to SARS-CoV-2 vaccination in patients on hemodialysis. Recipients of the mRNA-1273 vaccine had mean responses that were substantially larger than responses of BNT162b2 vaccine recipients, and were significantly more likely to achieve the higher antibody thresholds thought to be required for preventing infection. A multivariate analysis identified COVID-19 experience, vaccine type, use of immunosuppressive drugs, serum albumin, lymphocyte count, hepatitis B vaccine nonresponder status, and dialysis vintage as independent predictors of humoral and cellular responses. The strikingly better responses in mRNA-1273 recipients may be related to the vaccine’s higher mRNA content, suggesting that a high-dose vaccine may help improve SARS-CoV-2 vaccine effectiveness in patients on hemodialysis. Background: Preliminary evidence suggests patients on hemodialysis have a blunted early serological response to SARS-CoV-2 vaccination. Optimizing the vaccination strategy in this population requires a thorough understanding of predictors and dynamics of humoral and cellular immune responses to different SARS-CoV-2 vaccines. Methods: This prospective multicenter study of 543 patients on hemodialysis and 75 healthy volunteers evaluated the immune responses at 4 or 5 weeks and 8 or 9 weeks after administration of the BNT162b2 or mRNA-1273 vaccine, respectively. We assessed anti–SARS-CoV-2 spike antibodies and T cell responses by IFN-γ secretion of peripheral blood lymphocytes upon SARS-CoV-2 glycoprotein stimulation (QuantiFERON assay) and evaluated potential predictors of the responses. Results: Compared with healthy volunteers, patients on hemodialysis had an incomplete, delayed humoral immune response and a blunted cellular immune response. Geometric mean antibody titers at both time points were significantly greater in patients vaccinated with mRNA-1273 versus BNT162b2, and a larger proportion of them achieved the threshold of 4160 AU/ml, corresponding with high neutralizing antibody titers in vitro (53.6% versus 31.8% at 8 or 9 weeks, P<0.0001). Patients vaccinated with mRNA-1273 versus BNT162b2 exhibited significantly greater median QuantiFERON responses at both time points, and a larger proportion achieved the threshold of 0.15 IU/ml (64.4% versus 46.9% at 8 or 9 weeks, P<0.0001). Multivariate analysis identified COVID-19 experience, vaccine type, use of immunosuppressive drugs, serum albumin, lymphocyte count, hepatitis B vaccine nonresponder status, and dialysis vintage as independent predictors of the humoral and cellular responses. Conclusions: The mRNA-1273 vaccine’s greater immunogenicity may be related to its higher mRNA dose. This suggests a high-dose vaccine might improve the impaired immune response to SARS-CoV-2 vaccination in patients on hemodialysis.

1 November 2015 in Journal of Clinical Virology
Verified
Journal Article
Closed access
DSDeborah Steensels
Deborah Steensels
MRMarijke Reynders
Marijke Reynders
PDPatrick Descheemaeker
Patrick Descheemaeker
MCMartin D. Curran
Martin D. Curran
FJFrédérique Jacobs
Frédérique Jacobs
IMIsabel Montesinos
Isabel Montesinos

14 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LCLize Cuypers
Lize Cuypers
JBJannes Bode
Jannes Bode
KBKurt Beuselinck
Kurt Beuselinck
LLLies Laenen
Lies Laenen
KDKlaas Dewaele
Klaas Dewaele
EAEmmanuel André
Emmanuel André
From early 2020, a high demand for SARS-CoV-2 tests was driven by several testing indications, including asymptomatic cases, resulting in the massive roll-out of PCR assays to combat the pandemic. Considering the dynamic of viral shedding during the course of infection, the demand to report cycle threshold (Ct) values rapidly emerged. As Ct values can be affected by a number of factors, we considered that harmonization of semi-quantitative PCR results across laboratories would avoid potential divergent interpretations, particularly in the absence of clinical or serological information. A proposal to harmonize reporting of test results was drafted by the National Reference Centre (NRC) UZ/KU Leuven, distinguishing four categories of positivity based on RNA copies/mL. Pre-quantified control material was shipped to 124 laboratories with instructions to setup a standard curve to define thresholds per assay. For each assay, the mean Ct value and corresponding standard deviation was calculated per target gene, for the three concentrations (107, 105 and 103 copies/mL) that determine the classification. The results of 17 assays are summarized. This harmonization effort allowed to ensure that all Belgian laboratories would report positive PCR results in the same semi-quantitative manner to clinicians and to the national database which feeds contact tracing interventions.

23 August 2022 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
JOJulie Oosterbos
Julie Oosterbos
MSMaaike Schalkwijk
Maaike Schalkwijk
STSteven Thiessen
Steven Thiessen
EOEls Oris
Els Oris
GCGuy Coppens
Guy Coppens
DSDeborah Steensels
Deborah Steensels
Expanding the use of temocillin could be an important weapon in the fight against antimicrobial resistance. However, EUCAST defined clinical breakpoints for a limited number of species and only for urinary tract infections (UTI), including urosepsis but excluding severe sepsis and septic shock. Moreover, a dosage of 2 g q8h is advised in most cases. Evaluation of temocillin use for the treatment of bacteraemia, correlating clinical and microbiological outcomes with infection site, infection severity, temocillin dosage, Enterobacterales species and MIC. All adult patients with blood cultures positive for temocillin-susceptible Enterobacterales and treated with temocillin for ≥72 h from June 2018 until June 2021 were considered for inclusion. The primary outcome was clinical success, defined as resolution of infection signs, no relapse of the same infection and no antibiotic switch due to insufficient clinical improvement. The secondary outcome was microbiological success. In total, 182 episodes were included [140 UTI versus 42 non-UTI, 171 Escherichia coli, Klebsiella species (except Klebsiella aerogenes) and Proteus mirabilis (EKPs) versus 11 non-EKPs]. Clinical and microbiological failure were low (8% and 3%, respectively). No difference in outcome was observed for dosages of 2 g q12h versus 2 g q8h, either for EKP versus non-EKP isolates or MIC values ≤8 versus 16 mg/L. Considering only bacteraemia episodes of UTI origin, using the 16 mg/L breakpoint, there was no difference in success rate between regimens of 2 g q12h and 2 g q8h. Temocillin 2 g q12h can be successfully used for the treatment of systemic UTI. Prospective studies are needed to assess outcomes and evaluate non-inferiority compared with other broad-spectrum antibiotics in non-UTI infections, including bacteraemia.